/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Hoth Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.2 0.0526(5.26%) HOTH at 04 Dec 2025 04:34 PM Biotechnology
Lowest Today 1.155
Highest Today 1.26
Today’s Open 1.155
Prev. Close 1.14
52 Week High 2.79
52 Week Low 0.66
Day’s Range: Low 1.155 High 1.26
52-Week Range: Low 0.66 High 2.79
1 day return -
1 Week return -1.23
1 month return -9.43
3 month return -9.77
6 month return -21.05
1 year return +42.85
3 year return -68.5
5 year return -97.24
10 year return -

Institutional Holdings

Geode Capital Management, LLC 0.92

Vanguard Institutional Extnd Mkt Idx Tr 0.59

Fidelity Extended Market Index 0.48

UBS Group AG 0.32

Vanguard Group Inc 0.29

Fidelity Nasdaq Composite Index 0.24

Spartan Extended Market Index Pool F 0.13

Fidelity Total Market Index 0.12

Bank of Montreal 0.11

BMO Capital Markets Corp. 0.11

Foundations Investment Advisors, LLC 0.11

Fidelity Series Total Market Index 0.10

Two Sigma Investments LLC 0.08

Morgan Stanley - Brokerage Accounts 0.08

Spartan Total Market Index Pool G 0.06

Tower Research Capital LLC 0.05

Advisor Group Holdings, Inc. 0.02

NT Ext Equity Mkt Idx Fd - NL 0.01

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.01

State St US Extended Mkt Indx NL Cl C 0.01

Northern Trust Extended Eq Market Idx 0.01

NT Ext Equity Mkt Idx Fd - L 0.01

JONES FINANCIAL COMPANIES LLLP 0.00

SSgA U.S. Total Market Index Strategy 0.00

Federation des caisses Desjardins du Quebec 0.00

Royal Bank of Canada 0.00

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.00

NT Ext Eq Mkt Indx Fd DC Lend T3 0.00

Bank of America Corp 0.00

Northern Trust Wilshire 5000 0.00

Citigroup Inc 0.00

SBI Securities Co Ltd 0.00

BNP Paribas Arbitrage, SA 0.00

FLP Wealth Management, LLC 0.00

Virtu Financial LLC 0.00

Wells Fargo & Co 0.00

Market Status

Strong Buy: 1

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 17.69 M

PB Ratio 2.1485

PE Ratio 0.0

Enterprise Value 9.85 M

Total Assets 7.71 M

Volume 277557

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:-66834 -0.1M, FY21:-46871000 -46.9M, FY20:-25871 -0.0M, FY19:-31622 -0.0M

Annual Net worth FY23:-9621743 -9.6M, FY22:-11677362 -11.7M, FY21:-14313705 -14.3M, FY20:-7197816 -7.2M, FY19:-7694275 -7.7M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:-4354 -0.0M, Q3/2024:null 0.0M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-4105800 -4.1M, Q2/2025:-2199476 -2.2M, Q1/2025:-3475836 -3.5M, Q3/2024:-2132053 -2.1M, Q2/2024:-1632474 -1.6M

Fund house & investment objective

Company Information Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; and HT-004 for treatment of asthma and allergies using inhalational administration. The company is developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. The company was incorporated in 2017 and is headquartered in New York, New York.

Organisation Biotechnology

Employees 2

Industry Biotechnology

CEO Mr. Robb Knie

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow